GILEAD SCIENCES (GIS HM) stock market data APIs
€101.8794
-1.37(-1.3%)
as of October 31, 2025
Try our APIs with
free plan!
GILEAD SCIENCES Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GIS.HM.
Prev. Close
101.8794
Open
100.5118
High
101.8794
Low
100.5118
52 wk Range
79.6035-108.6037
Market Cap
78 028 M
Dividends (Yield)
0.0266
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GILEAD SCIENCES data using free add-ons & libraries
Get GILEAD SCIENCES Fundamental Data
GILEAD SCIENCES Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 2.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GILEAD SCIENCES News
New
Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot
Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot. Continue Reading View Comments
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product sales. Adjusted earnings per share (EPS) of $2.47 beat the Zacks Consensus Est...
GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations , with sales up 3% year on year to $7.77 billion. On the other hand, the ...
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
HOOKIPA Pharma Inc. NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
